Decreased expression of ARID1A is related to the poor prognosis of glioma patients

Purpose: This study intended to determine the expression of AT rich interactive domain 1A (SWI-like) (ARID1A) in serum of glioma patients and explore the relevance between ARID1A expression and the prognosis of glioma patients. Methods: The expression of ARID1A in serum of glioma patients and healthy controls were measured by high performance liquid chromatography (HPLC). Chi-square test was applied to evaluate the statistical difference between ARID1A expression and the clinicopathologic characteristics. Kaplan-Meier analysis combing with log-rank test was used to compare the overall survival of glioma patients with different ARID1A expression. Cox regression analysis was performed to evaluate the relationship between ARID1A expression and the prognosis of glioma patients. Results: The ARID1A expression was significantly lower in serum of glioma patients than in the healthy controls (P < 0.001). Moreover, the ARID1A expression was closely related to pathological grading, age and KPS score (P < 0.05), while no relationship was found between ARID1A expression and gender, preoperative epilepsy, or tumor range (P > 0.05). Besides, the overall survival time of patients with high ARID1A expression was significantly longer than those with low ARID1A expression according to Kaplan-Meier analysis (P = 0.005). Cox regression analysis illustrated that ARID1A expression was a potential factor for prognosis of glioma patients and it might be an independent biomarker (P = 0.002, HR = 4.992, 95% CI = 1.831-13.611). Conclusion: In a word, our study indicated that down-regulation of ARID1A was a promising biomarker for the prognosis of glioma patients.